BERMUDA-BUSINESS-DEVELOP
17.10.2019 19:42:06 CEST | Business Wire | Press release
Premier David Burt officially opened the Bermuda Tech Summit yesterday and announced the country would begin accepting 1:1 U.S. dollar-backed digital currencies for the payment of government taxes, fees and services as part of its efforts to ensure Bermuda continues to lead the development of the global fintech industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005802/en/
Throughout the day, more than 300 attendees, a third of whom travelled to Bermuda from overseas, heard from an impressive array of expert speakers who discussed the transformational impact of technology on investment and business models in a wide range of industry sectors relevant to Bermuda. The Bermuda Business Development Agency (BDA) hosted the free-to-attend summit, titled ‘Focused on the Future,’ in partnership with FinTech Bermuda.
“Technology is the future. If you look at five of the six largest companies in the world today, they are technology companies,” said Premier Burt during the opening keynote conversation with Circle CEO Jeremy Allaire. “We know that embracing new technology is necessary for the future growth of our economy, and so, in Bermuda, we are making sure that we are leading the world in facilitating innovation. If existing and new businesses cannot innovate in Bermuda, they will find other jurisdictions to innovate meaning Bermuda will lose out on opportunities. It is essential that Bermuda remains a centre of innovation and continues to improve our competitive advantage in financial services.”
On why he chose Bermuda to operate his business, Jeremy Allaire said: “To build our international business we needed to find a jurisdiction that understood the breadth of digital assets and the scope of what we want to achieve. Bermuda is way ahead than any other country in this regard. As the adoption of digital currencies becomes mainstream, countries like Bermuda who are participating in the innovation stand to benefit and are helping to create a world where the exchange of value is as efficient, free and open as the exchange of information, knowledge and content is today.”
Keynote speaker Terence Mills, CEO of Al.io and a member of the Forbes Technology Council contributing on the topic of artificial intelligence (AI), spoke to a packed room about the future of work, and the challenges and potential of integrating AI into workflows. He gave an engaging presentation on using technology to drive efficiencies with the U.S. healthcare system as an example case.
Other panels highlighted relevant themes such as the increasing demand from customers for connectivity in hospitality, remote working as a future business model in place of an office and thinking inclusively when it comes to building technological infrastructure. It was clear based on discussions throughout the day that realising the grand promise of innovation and new technology requires a collaborative effort and support from both the public and private sectors.
“The tech-savvy and modern business approach that Bermuda is inculcating serves to enhance our appeal in the eyes of the next generation of business leaders, investors and high-net-worths,” said BDA CEO Roland Andy Burrows during his welcome remarks. “Bermuda has long been a domicile of choice for insurance, asset management and trusts amongst many other industries, thanks to the stability, quality and ease of doing business it offers. A combination of these same features, along with our future-focused approach, are now attracting technologists and innovators, the likes of whom are with us today.”
The Bermuda Tech Summit was the capstone event of the inaugural Bermuda Tech Week 2019, which continues tomorrow with Tech Beach Retreat, which is being held in Bermuda for the first time.
Sponsors and partners throughout the week include 24 Exchange, Appleby, Argo Group, Bermuda Economic Development Corporation, Bermuda Tourism Authority, Blockchain Triangle, Blockchain Radio, ChainThat, Circle, Conyers, Google, Gosling’s, Swan Group, The Royal Gazette, Walkers and Xceedance.
Learn more about Bermuda Tech Week 2019 by visiting www.bermudatechweek.bm .
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005802/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
